A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis

T. J. Schnitzer, J. R P Tesser, K. M. Cooper, Roy D Altman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA). Methods: Four hundred and three adult patients with moderate pain secondary to knee OA were randomized to receive APAP ER 1300 mg three times daily, rofecoxib 12.5 mg once daily, or rofecoxib 25 mg once daily. Primary end point was change from baseline at week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score using a visual analog scale. This 4-week study was conducted at 23 US research sites from October 1999 to October 2000. Results: APAP ER was noninferior to rofecoxib 12.5 mg because the upper 95% confidence limit (CL) for the least squares mean (LSM) change from baseline (35.27 mm at week 4) did not exceed the prespecified noninferiority limit of 50 mm. The upper CL (57.39 mm) exceeded the noninferiority limit for APAP ER compared with rofecoxib 25 mg at week 4. There were no significant differences among groups in the overall incidence of adverse events. Conclusion: APAP ER 3900 mg daily was noninferior to rofecoxib 12.5 mg daily, but noninferiority was not established to rofecoxib 25 mg daily. APAP ER was well tolerated and no safety issues were identified. Based on the results of this study, APAP ER 3900 mg daily is an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalOsteoarthritis and Cartilage
Volume17
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Knee Osteoarthritis
Acetaminophen
Pain
Safety
rofecoxib
Ontario
Pain Management
Least-Squares Analysis
Visual Analog Scale
Osteoarthritis
Anti-Inflammatory Agents
Incidence
Research
Pharmaceutical Preparations

Keywords

  • Acetaminophen extended-release
  • Knee
  • Osteoarthritis
  • Rofecoxib

ASJC Scopus subject areas

  • Biomedical Engineering
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. / Schnitzer, T. J.; Tesser, J. R P; Cooper, K. M.; Altman, Roy D.

In: Osteoarthritis and Cartilage, Vol. 17, No. 1, 01.2009, p. 1-7.

Research output: Contribution to journalArticle

Schnitzer, T. J. ; Tesser, J. R P ; Cooper, K. M. ; Altman, Roy D. / A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. In: Osteoarthritis and Cartilage. 2009 ; Vol. 17, No. 1. pp. 1-7.
@article{de8a068b5b474a8ca30ebaf65161fbb2,
title = "A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis",
abstract = "Objective: To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA). Methods: Four hundred and three adult patients with moderate pain secondary to knee OA were randomized to receive APAP ER 1300 mg three times daily, rofecoxib 12.5 mg once daily, or rofecoxib 25 mg once daily. Primary end point was change from baseline at week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score using a visual analog scale. This 4-week study was conducted at 23 US research sites from October 1999 to October 2000. Results: APAP ER was noninferior to rofecoxib 12.5 mg because the upper 95{\%} confidence limit (CL) for the least squares mean (LSM) change from baseline (35.27 mm at week 4) did not exceed the prespecified noninferiority limit of 50 mm. The upper CL (57.39 mm) exceeded the noninferiority limit for APAP ER compared with rofecoxib 25 mg at week 4. There were no significant differences among groups in the overall incidence of adverse events. Conclusion: APAP ER 3900 mg daily was noninferior to rofecoxib 12.5 mg daily, but noninferiority was not established to rofecoxib 25 mg daily. APAP ER was well tolerated and no safety issues were identified. Based on the results of this study, APAP ER 3900 mg daily is an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.",
keywords = "Acetaminophen extended-release, Knee, Osteoarthritis, Rofecoxib",
author = "Schnitzer, {T. J.} and Tesser, {J. R P} and Cooper, {K. M.} and Altman, {Roy D}",
year = "2009",
month = "1",
doi = "10.1016/j.joca.2008.05.018",
language = "English (US)",
volume = "17",
pages = "1--7",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis

AU - Schnitzer, T. J.

AU - Tesser, J. R P

AU - Cooper, K. M.

AU - Altman, Roy D

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA). Methods: Four hundred and three adult patients with moderate pain secondary to knee OA were randomized to receive APAP ER 1300 mg three times daily, rofecoxib 12.5 mg once daily, or rofecoxib 25 mg once daily. Primary end point was change from baseline at week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score using a visual analog scale. This 4-week study was conducted at 23 US research sites from October 1999 to October 2000. Results: APAP ER was noninferior to rofecoxib 12.5 mg because the upper 95% confidence limit (CL) for the least squares mean (LSM) change from baseline (35.27 mm at week 4) did not exceed the prespecified noninferiority limit of 50 mm. The upper CL (57.39 mm) exceeded the noninferiority limit for APAP ER compared with rofecoxib 25 mg at week 4. There were no significant differences among groups in the overall incidence of adverse events. Conclusion: APAP ER 3900 mg daily was noninferior to rofecoxib 12.5 mg daily, but noninferiority was not established to rofecoxib 25 mg daily. APAP ER was well tolerated and no safety issues were identified. Based on the results of this study, APAP ER 3900 mg daily is an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.

AB - Objective: To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA). Methods: Four hundred and three adult patients with moderate pain secondary to knee OA were randomized to receive APAP ER 1300 mg three times daily, rofecoxib 12.5 mg once daily, or rofecoxib 25 mg once daily. Primary end point was change from baseline at week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score using a visual analog scale. This 4-week study was conducted at 23 US research sites from October 1999 to October 2000. Results: APAP ER was noninferior to rofecoxib 12.5 mg because the upper 95% confidence limit (CL) for the least squares mean (LSM) change from baseline (35.27 mm at week 4) did not exceed the prespecified noninferiority limit of 50 mm. The upper CL (57.39 mm) exceeded the noninferiority limit for APAP ER compared with rofecoxib 25 mg at week 4. There were no significant differences among groups in the overall incidence of adverse events. Conclusion: APAP ER 3900 mg daily was noninferior to rofecoxib 12.5 mg daily, but noninferiority was not established to rofecoxib 25 mg daily. APAP ER was well tolerated and no safety issues were identified. Based on the results of this study, APAP ER 3900 mg daily is an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.

KW - Acetaminophen extended-release

KW - Knee

KW - Osteoarthritis

KW - Rofecoxib

UR - http://www.scopus.com/inward/record.url?scp=57349156921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349156921&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2008.05.018

DO - 10.1016/j.joca.2008.05.018

M3 - Article

VL - 17

SP - 1

EP - 7

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 1

ER -